At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
In the news
2 articles- Lilly maintains deal streak with $1.2B pact for Hanmi's GLP-2 candidateBioSpace·2026-06-01
- <a href="https://www.fiercebiotech.com/biotech/lilly-pens-12b-deal-hanmis-glp-2-drug-being-aimed-short-bowel-syndrome" hreflang="en">Lilly pens $1.2B deal for Hanmi’s GLP-2 drug being aimed at short bowel syndrome</a>FierceBiotech
Matched to this trial by ClinicalIndexfrom reputable biotech & medical press.
The Role of the Intestinal Hormones Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide 2 (GLP-2) in Postprandial Splanchnic Blood Flow Distribution and Metabolism in Humans
In Brief
A clinical study evaluating GIPR antagonist / study tool, GLP-2R antagonist / study tool, and 1 other intervention for Blood Flow. Completed, enrolled 10 participants across 1 site.
Detailed Summary
This project will describe the mechanisms of action and the relative contributions of GIP and GLP-2 to changes in gastrointestinal blood flow induced by oral glucose, exogenous GIP and GLP-2 infusions, and endogenous GIP and GLP-2 with the use of two novel receptor antagonists GIP(3-30)NH2 and GLP-2(3-33) in healthy individuals.
Study Details
Timeline
Interventions
Selective antagonist of the GIPR, GIP(3-30)NH2
Selective antagonist of the GLP-2R, GLP-2(3-33)
Saline